RA CAPITAL MANAGEMENT, L.P.
Institutional investor · Portfolio as of Q2 2020
Top Holdings57 positions
ASCENDIS PHARMA A/S | 4.9M | $726.9M | 14.2% | $69.04 | +110.33% | 7 qtrssince 2018-Q4 | Unchanged 0 |
FORMA THERAPEUTICS HLDGS INC | 9M | $419M | 8.2% | — | — | 1 qtr | New 96 |
NOVAVAX INC | 4.8M | $396.6M | 7.7% | $83.61 | 0.00% | 1 qtr | New 96 |
| 4.8M | $277.7M | 5.4% | — | — | 3 qtrssince 2019-Q4 | Increased 69 | |
TG THERAPEUTICS INC | 12.8M | $249.1M | 4.9% | $8.58 | +116.44% | 7 qtrssince 2018-Q4 | Increased 68 |
VAXCYTE INC | 5.5M | $173.5M | 3.4% | $31.20 | 0.00% | 1 qtr | New 84 |
AXSOME THERAPEUTICS INC | 2M | $167.5M | 3.3% | $50.95 | +49.86% | 6 qtrssince 2019-Q1 | Increased 60 |
ADVERUM BIOTECHNOLOGIES INC | 7.8M | $162.9M | 3.2% | — | — | — | Increased 60 |
SATSUMA PHARMACEUTICALS INC | 4.7M | $134.7M | 2.6% | — | — | 4 qtrssince 2019-Q3 | Unchanged 0 |
ADAPTIMMUNE THERAPEUTICS PLC | 13.1M | $130.7M | 2.5% | $3.01 | +209.07% | 2 qtrssince 2020-Q1 | Increased 54 |
MACROGENICS INC | 4.6M | $128M | 2.5% | $28.28 | 0.00% | 1 qtr | New 78 |
PHATHOM PHARMACEUTICALS INC | 3.8M | $125.9M | 2.5% | $32.43 | +3.67% | 3 qtrssince 2019-Q4 | Increased 53 |
ARVINAS INC | 3.7M | $123.2M | 2.4% | $29.09 | +9.83% | 7 qtrssince 2018-Q4 | Unchanged 0 |
RHYTHM PHARMACEUTICALS INC | 5.2M | $116.2M | 2.3% | $23.93 | -6.83% | 7 qtrssince 2018-Q4 | Decreased 0 |
KALA PHARMACEUTICALS INC | 10.9M | $114.3M | 2.2% | — | — | — | Unchanged 0 |
BLACK DIAMOND THERAPEUTICS I | 2.6M | $109.2M | 2.1% | $25.40 | +56.65% | 2 qtrssince 2020-Q1 | Unchanged 0 |
LEGEND BIOTECH CORP | 2.5M | $105.6M | 2.1% | $41.10 | 0.00% | 1 qtr | New 78 |
EIDOS THERAPEUTICS INC | 2.2M | $103.1M | 2.0% | — | — | 7 qtrssince 2018-Q4 | Unchanged 0 |
ALECTOR INC | 4.1M | $100.9M | 2.0% | $23.10 | +1.73% | 6 qtrssince 2019-Q1 | Unchanged 0 |
ZOGENIX INC | 3.7M | $99.3M | 1.9% | — | — | 7 qtrssince 2018-Q4 | Decreased 0 |
RA CAPITAL MANAGEMENT, L.P. manages $5.1B across 57 positions as of Q2 2020. Top holdings: ASND (14.2%), FMTX (8.2%), NVAX (7.7%). Fund DNA: Balanced Allocator. HoldingsIntel Score: 2.5/5.0.
Active quarter - 18 new positions, 9 exits, 9 increased. Top move: FMTX (NEW, conviction 96). Portfolio: $5.1B across 57 positions.
Top holdings by portfolio weight
Portfolio allocation by GICS sector
Behavioral investing profile
Position Outcomes
Best and worst performing positions by estimated return
Top Winners
Top Losers
Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.
Similar Funds
Funds with similar investing DNA
Explore More
Accumulation Streaks
Positions with 2+ consecutive quarters of increases - persistent directional conviction.
Continue exploring
Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer
Verify source filings on SEC EDGAR